MINNEAPOLIS, July 7, 2011 /PRNewswire/ -- ProUroCare Medical Inc. (OTCQB: PUMD), a provider of proprietary medical imaging products announced today the election of Larry W. Getlin to its Board of Directors.
During the past eight months, Getlin has served as a consultant to the company assisting on its FDA "de novo" market clearance application for its ProUroScan system and in developing an effective communication channel with the agency. He has also been instrumental in addressing strategic issues for the company related to current and future regulatory actions.
According to Rick Carlson, ProUroCare's CEO, "Larry is an outstanding addition to our Board bringing 19 years of urology regulatory, clinical affairs, quality and compliance experience. We believe this experience and the relationships he has established within the medical device industry and the global regulatory environment over his 35-year career will be important to us as we pursue new FDA clearances and establish the internal compliance programs required to enter the prostate disease market. His background is representative of the caliber of personnel we intend to add to our Board and management teams moving forward."
Getlin served as Senior Vice President of Corporate Compliance, Legal and Quality at American Medical Systems from June of 2006 to April of 2010, and as Vice President of Regulatory, Clinical Affairs and Quality Systems for 15 years before that time. Prior to joining American Medical Systems he directed U.S. and international regulatory approval programs and GMP compliance initiatives at the Pharmaseal Division of Baxter Healthcare for over 14 years. Getlin contributed to the revised and restated AdvaMed Code of Ethics on Interactions with Health Care Professionals. He is also a member of the California State Bar Association, American Bar Association, Health Law Section and the Regulatory Affairs Professional Society (RAPS).
About ProUroCare Medical Inc.
ProUroCare Medical Inc. is a publicly traded company engaged in the business of developing innovative medical imaging products. The company's ProUroScan system, an elasticity imaging technology used to document abnormalities of the prostate previously detected by a digital rectal examination, is currently under review by the FDA for commercial clearance.
Safe Harbor Statement
This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of ProUroCare's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause ProUroCare's results to differ materially from those expressed or implied by such forwardlooking statements include, but are not limited to, the ability of ProUroCare to find adequate financing to complete the development of its products; the high level of secured and unsecured debt incurred by ProUroCare; the impact and timing of actions taken by the FDA and other regulatory agencies with respect to ProUroCare's products and business; the dependence by ProUroCare on third parties for the development and manufacture of its products; and other risks and uncertainties detailed from time to time in ProUroCare's filings with the Securities and Exchange Commission including its most recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no duty to update any of these forward-looking statements.
SOURCE ProUroCare Medical Inc.